We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.82%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$13.3B
AUM Growth
+$1.51B
Cap. Flow
+$1.01B
Cap. Flow %
7.58%
Top 10 Hldgs %
83.56%
Holding
124
New
10
Increased
16
Reduced
22
Closed
5

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$1.09B
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$84.2M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$54.3M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$44.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$144M
2
ABLX
Ablynx NV
ABLX
+$119M
3
NKTR icon
Nektar Therapeutics
NKTR
+$29.3M
4
EXEL icon
Exelixis
EXEL
+$13.4M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.38%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$3.39B 25.46%
51,046,060
+1,470,651
+3% +$84.2M
INCY icon
2
Incyte
INCY
$25.3B
$2.29B 17.24%
34,251,034
+20,283
+0.1% +$1.39M
ONC
3
BeOne Medicines Ltd
ONC
$34.1B
$1.84B 13.81%
11,959,824
+6,130,395
+105% +$1.09B
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$1.06B 7.98%
8,555,894
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12B
$714M 5.37%
7,583,084
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$695M 5.22%
13,790,574
+638
+0% +$25.3K
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$4.46B
$416M 3.12%
27,228,338
– –
MDGL icon
8
Madrigal Pharmaceuticals
MDGL
$12.5B
$327M 2.46%
1,169,278
+553,594
+90% +$97.2M
HRTX icon
9
Heron Therapeutics
HRTX
$92.6M
$195M 1.47%
5,025,298
– –
ASND icon
10
Ascendis Pharma A/S
ASND
$16.7B
$189M 1.42%
2,837,352
– –
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$124M 0.93%
2,513,462
-35,999
-1% -$1.36M
ONCE
12
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$115M 0.86%
1,384,130
– –
DBVT
13
DBV Technologies
DBVT
$798M
$106M 0.8%
550,956
– –
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$96M 0.72%
613,300
-33,528
-5% -$5.26M
ARRY
15
DELISTED
Array Biopharma Inc
ARRY
$94.9M 0.71%
5,656,196
– –
NBIX icon
16
Neurocrine Biosciences
NBIX
$18.3B
$92.8M 0.7%
944,624
– –
RYTM icon
17
Rhythm Pharmaceuticals
RYTM
$7.38B
$84.7M 0.64%
2,708,200
+659,180
+32% +$18M
BCRX icon
18
BioCryst Pharmaceuticals
BCRX
$2.44B
$80.3M 0.6%
14,012,172
– –
ARGX icon
19
argenx
ARGX
$55.2B
$79.7M 0.6%
961,754
– –
CERS icon
20
Cerus
CERS
$577M
$71.7M 0.54%
10,749,937
– –
AMRN
21
Amarin Corp
AMRN
$294M
$70M 0.53%
1,133,475
– –
CBAY
22
DELISTED
Cymabay Therapeutics
CBAY
$66M 0.5%
4,917,700
+1,000,000
+26% +$12.5M
NVTA
23
DELISTED
Invitae Corporation
NVTA
$61.7M 0.46%
8,399,411
– –
KNSA icon
24
Kiniksa Pharmaceuticals
KNSA
$6.13B
$52M 0.39%
+3,000,000
New +$54.3M
ACGN
25
DELISTED
Aceragen Inc
ACGN
$51M 0.38%
284,511
+98
+0% +$22.9K
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Baker Bros. Advisors held 124 positions worth $13.3B, up 13% from $11.8B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors deployed $1.01B of net new capital in Q2 2018, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Exelixis, an estimated $13.4M trimmed.

  • Baker Bros. Advisors's largest Q2 2018 buy was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q2 2018, an estimated $1.09B increase.
  • Baker Bros. Advisors's biggest Q2 2018 reduction was Exelixis, cutting an estimated $13.4M.
  • Baker Bros. Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $13.3B portfolio in Q2 2018.
  • Baker Bros. Advisors opened 10 new positions and closed 5 in Q2 2018.
  • Baker Bros. Advisors's portfolio value rose 13% quarter-over-quarter to $13.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.